As a full-service clinical CRO, CR2O supports biotech and pharmaceutical companies throughout the entire product development journey — from clinical trial design to regulatory approval. Our team looks forward to meeting innovators and investors who share our mission to advance science through reliable and efficient clinical research.
Successful participation and inspiring connections in Amsterdam
CR2O was proud to participate in the World Vaccine Congress Europe 2025, held at the RAI Convention Center in Amsterdam. As one of the leading events in vaccine development, clinical research, and biopharmaceutical innovation, the congress brought together more than 2,500 global experts, 280 speakers, and 150 exhibitors from across the vaccine landscape.
Prepare for a game-changing collaboration! InnoSer and CR2O unveil their strategic partnership, bridging the gap between pre-clinical and clinical research. Join us as we revolutionize drug discovery and development with an integrated platform poised to accelerate groundbreaking treatments to market.
Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and U.S. firms.
A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a well-organized set of action plans needs to be in place that guides and accelerates the client’s vision on how to support their targeted therapeutic area.
Our highly qualified and experienced Life Sciences professionals are supported by CR2O’s rigorous clinical quality management system and continuous training programs, enabling delivery of top-quality clinical services. Senior experts were selected based on their ability to answer to the client’s development program’s specific requirements. The combined teams of Non-Clinical, Clinical, CMC and Regulatory experts all had hands-on experience from leading Big Pharma company teams.
Going from bench to the patient’s bedside is the dream of any scientist. Working smarter can make this goal a reality. Having a clear plan and guidance from the first tests all the way to the final drug product is crucial. Being able to combine CR2O’s operational clinical expertise with Clinical Science, CMC, Regulatory Affairs and Non-Clinical expertise was shown to be vital in those projects.
As a result of the COVID-19 pandemic, CR2O has adapted its contingency plan aimed to guarantee the safety and well-being of patients, employees, clients and continuity of our services. By following recommendations from Regulatory Authorities (local, EMA and FDA), CR2O continues to focus on patient safety and maintaining compliance with GCP under the current restrictive circumstances.
Spokespeople
